Navigation Links
Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Release of Study Finding Tylenol Use in Pregnancy May Affect Child Development
Date:12/19/2013

New York, NY (PRWEB) December 19, 2013

As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/) continue to mount in courts around the country, Bernstein Liebhard LLP notes that a newly published study has reported a possible association between the use of acetaminophen in pregnancy and problems with child development. Acetaminophen is the active ingredient in Tylenol-brand over-the-counter medications.

The study, which was published online in the International Journal of Epidemiology, looked at 8,000 Norwegian children whose mothers were surveyed about their medication use at weeks 17 and 30 of pregnancy. They were also surveyed at 6 months post-partum, and were asked to complete a follow-up questionnaire about their child's developmental milestones three years later. The children of women who reported the most frequent acetaminophen use (at least 28 days during pregnancy) appeared to exhibit poorer motor, language and communication skills than other children. They also had more behavior problems, according to the authors of the study.*

“While the lawsuits we are investigating involve allegations that Tylenol can cause severe liver damage, this study serves to remind that acetaminophen may carry some very real risks,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to individuals who may have suffered liver damage associated with the use of Tylenol.

Tylenol and Liver Damage
According to the U.S. Food & Drug Administration (FDA), acetaminophen was the leading cause of acute liver failure in the U.S. between 1998 and 2003. From 1990 to 1998, acetaminophen was blamed for 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths annually.

According to court documents, at least 100 Tylenol lawsuits involving liver damage allegations are now pending in a federal multidistrict litigation underway in U.S. District Court, Eastern District of Pennsylvania. All of the lawsuits allege that Tylenol products can cause liver damage, even when taken as directed. The lawsuits further allege that many victims of Tylenol liver damage were hospitalized, required a liver transplant, or died, as a result of acetaminophen in the over-the-counter medications. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)

This past summer, Johnson & Johnson announced it was adding more prominent, red-lettered warnings to the labels of Tylenol products regarding the potential for sever liver damage. According to a report from Bloomberg.com, Extra Strength Tylenol – which contains 500 milligrams of acetaminophen per tablet - was to appear with the warnings in October. Other products will bear the warnings in the coming months.**

Individuals who suffered acetaminophen-induced liver damage resulting in hospitalization, liver transplantation or death allegedly associated with a Tylenol product may be entitled to compensation for medical expenses and other injury-related damages. Find out more about filing a Tylenol lawsuit by visiting Bernstein Liebhard LLP’s website. For a free evaluation of your claim, please call 800-511-5092.

*ije.oxfordjournals.org/content/early/2013/10/24/ije.dyt183.abstract, Journal of Epidemiology, October 2013
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/tylenol-lawsuit/tylenol-liver-damage/prweb11438415.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Tylenol Liver Problem Allegations Help: Resource4thePeople Comments on Legal Developments
2. Tylenol Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Tylenol Litigation
3. Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Filing of New Claim Alleging Use of Tylenol Caused Liver Damage
4. Tylenol Liver Damage Allegations Lawyer Help: Resource4thePeople Reports Judge Outlines Procedures for Bellwether Trials
5. Injury Law Firm Comments on the FDA Consumer Update Warning about Tylenol Side Effects like SJS
6. Tylenol Lawsuit News: New Jersey Supreme Court Refuses Multicounty Case Consolidation, Rottenstein Law Group LLP Reports
7. Latest Tylenol Liver Failure Lawsuit Allegations Report: Resource4thePeople Urges Consumers to Fully Inform Themselves about Liver Disease Danger Possibility
8. Rottenstein Law Group LLP Announces New Tylenol Lawsuit Center
9. Update on Alleged Tylenol Liver Failure Lawsuits from Resource4thePeople: Judge Selects Steering Committee in Multidistrict Litigation
10. Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center
11. Anxious about life? Tylenol may do the trick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: